相关实验视频
Updated: Jan 12, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
Published on: July 3, 2020
2型自体逆性低酸性狂犬病 (ARHR2):补充酸是安全的吗?
Martin Munteanu1, Frank Rutsch2, Yvonne Nitschke2
1Department of Pediatrics II, University of Duisburg-Essen, University Hospital Essen (member of ENDO-ERN; member of BOND- ERN), Essen, Germany; Institute of Human Genetics, University Medical Center Göttingen, Georg-August-University, Göttingen, Germany.
自体逆向性低酸性狂犬病2型 (ARHR2) 的管理是复杂的. 酸盐补充剂在ARHR2患者中存在血管化的风险,需要仔细监测和替代治疗策略.
科学领域:
- 遗传学和罕见疾病.
- 内分泌学和新陈代谢
- 儿童骨疾病 儿童骨疾病
背景情况:
- 2型自体逆性低酸性恶心病 (ARHR2) 涉及脏酸的浪费和潜在的血管化.
- 酸盐补充剂是一种常见的治疗方法,可以通过增加酸产品来加剧化风险.
研究的目的:
- 扩大已知的ARHR2和异性ENPP1变体载体的表型.
- 评估与ARHR2患者酸盐补充剂相关的安全问题.
主要方法:
- 一个儿科ARHR2患者的长度随访超过11年.
- 评估骨和骨外表现,包括对酸盐补充剂的反应.
- 对四个异合体家族成员的表型分析,以探索载体含义.
主要成果:
- 在ARHR2患者中发现了一种同卵性ENPP1变体 (c.2677G>T,p.(Glu893*).
- 患者在补充酸盐后出现了渐进的骨症状和血管化.
- 异卵性家族成员表现出轻微的代谢变化,表明潜在的亚临床表型.
结论:
- 准确的基因诊断对于管理ARHR2至关重要.
- 酸盐补充剂在ARHR2中具有显著的血管化风险.
- 未来的疗法应侧重于安全的酸盐校正,可能通过联合策略或酶替代,与必要的心血管监测.
相关概念视频
Introduction to Electrolytes
Role of Sodium
One...
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily...
Chronic Kidney Disease III: Interprofessional Care
Phosphate Buffer
Sodium dihydrogen phosphate does not fully dissociate in neutral or acidic solutions. When a strong base, such as sodium hydroxide (NaOH), is introduced into the solution, sodium dihydrogen phosphate...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism

